Treatment decisions during pregnancy involve navigating complex tradeoffs between maternal mental health and fetal safety, with severe perinatal depression presenting particularly challenging clinical scenarios. Two non-pharmacological interventions are gaining recognition as viable alternatives when medication risks become prohibitive or when rapid symptom control is essential. Electroconvulsive therapy continues to demonstrate efficacy for pregnant individuals experiencing severe, treatment-resistant depression or acute suicidal ideation, offering potentially life-saving rapid symptom resolution. The procedure's established safety profile during pregnancy, combined with its speed of action, makes it particularly valuable for crisis situations where delayed treatment poses immediate risks. Transcranial magnetic stimulation represents a newer addition to the perinatal treatment landscape, with accumulating evidence supporting its use in selected cases. This non-invasive brain stimulation technique offers the advantage of avoiding both medication exposure and the anesthesia requirements of ECT. However, clinical experts emphasize that these specialized interventions complement rather than replace pharmacological approaches for most cases. The majority of pregnant individuals with moderate to severe depression who don't require hospitalization find medications remain the most practical path to symptom management and risk reduction. This treatment hierarchy reflects the reality that while non-pharmacological options provide crucial alternatives for specific clinical scenarios, they require specialized facilities and expertise that may not be readily accessible. The evolving perinatal depression treatment paradigm increasingly emphasizes individualized risk-benefit analyses, considering severity, treatment history, access to specialized care, and patient preferences in developing optimal therapeutic strategies.